TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05059951
Drug: Immune checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy follow the guild line.
Study: NCT06243822
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine is initiated at 0.5 mg/kg/h and titrated by 0.25 mg/kg/h every 15 minutes to a maximum dosage of 4 mg/kg/h to achieve appropriate sedation.
Study: NCT06243822
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol is initiated at 0.3 to 0.6 mg /kg/hr. and titrated by 0.3 to 0.6 mg/kg/h every 5 to 10 minutes up to a maximum dosage of 4.5 to 4.8 mg/kg/hr. to achieve appropriate sedation.
Study: NCT05398393
Drug: oral Tenofovir Amibufenamide 25mg each day
Normalized name: Tenofovir amibufenamide
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients in three groups respectively take one tablet of Tenofovir Amibufenamide(25mg) every day
Study: NCT05734794
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days), associated with trimethoprim-sulfamethoxazole(25-50 mg/kg/day orally twice per day, 3 days per week. If the patient is not allergic) for three months from the first rituximab dosing date(Day 1). Four doses of rituximab are necessary whether the patient achieves complete remission.
Study: NCT05041673
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antidiabetic drugs
Study: NCT06369350
Drug: Vitamin B6 25 MG
Normalized name: vitamin B6 25 MG
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 25 mg/day will be given for up to 31 days.
Study: NCT06369350
Drug: Vitamin B6 50 MG
Normalized name: vitamin B6 50 MG
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 50 mg/day will be given for up to 31 days.
Study: NCT06369350
Drug: Vitamin B6 100 MG
Normalized name: vitamin B6 100 MG
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 100 mg/day will be given for up to 31 days.
Study: NCT05290558
Drug: Bu Shen Yi Jing Pill
Normalized name: Ren shen
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bu Shen Yi Jing Pill contained Radix Pseudostellaria, Fructus Lycii, Radix Et Rhizoma Salviae, Rhizoma Dioscorea, Semen Plantaginis, Semen Cuscuta, Patriniae Herba, Herba Epimedii, Radix Ophiopogonis, Fructus Rubi, Fructus Corni, Bupleurum roots, Fructus Schisandrae Chinensis, Radix Et Rhizoma Glycyrrhizae.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year
Study: NCT06490198
Drug: OBI-833/OBI-821
DrugBank: OBI-833 (DB19270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBI-833 is a glycoconjugate that consists of Globo H, a unique tumor-associated carbohydrate antigen (TACA), covalently linked to cross-reacting material 197 (CRM197), an inactive and nontoxic form of diphtheria toxin (DT) acting as the carrier protein.~OBI-821 is a saponin-based adjuvant derived from the bark of the Quillaja saponaria Molina tree. It is a purified saponin adjuvant structurally similar to adjuvant QS-21. The OBI-833/OBI-821 combination represents a carbohydrate-conjugate vaccine combined with an immune adjuvant, intended to serve as an active cancer immunotherapy.
Study: NCT04159077
Drug: Tamsulosin Hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin HCL is an alpha blocker. It relaxes the muscles in the prostate and bladder neck, making easier to urinate. The dosage used will be 0.4 mg (administered once daily)~Other names: Flomax
Study: NCT06735443
Drug: Bupivacaine with Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with 1 mg/kg of tramadol. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.
Study: NCT05557942
Drug: AV-101
Normalized name: AV-101
DrugBank: AV-101 (DB12878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV-101 (imatinib) administered via dry powder inhalation
Study: NCT05779579
Drug: HS-10517 Dose 1
Normalized name: lanolin 0.0517 MG/MG
DrugBank: Lanolin (DB11112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10517 Dose 1+Ritonavir
Study: NCT05779579
Drug: HS-10517 Dose 2
Normalized name: lanolin 0.0517 MG/MG
DrugBank: Lanolin (DB11112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10517 Dose 2+Ritonavir
Study: NCT05779579
Drug: HS-10517 Dose 3
Normalized name: lanolin 0.0517 MG/MG
DrugBank: Lanolin (DB11112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10517 Dose 3+Ritonavir
Study: NCT05779579
Drug: HS-10517 Dose 4
Normalized name: lanolin 0.0517 MG/MG
DrugBank: Lanolin (DB11112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10517 Dose 4+Ritonavir
Study: NCT00041691
Drug: hMN14 (labetuzumab)
Normalized name: MAb hMN14
DrugBank: Labetuzumab (DB05097)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06218667
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level 1 (starting dose): 45 mg of copanlisib IV weekly x 3 weeks on/1 week off Dose level 2 (standard dose): 60 mg of copanlisib IV weekly x 3 weeks on/1 week off
Study: NCT06218667
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix (GnRH antagonist): 240 mg loading dose sub-cutaneous once on C1D1; 80 mg maintenance dose on C2D1 and C3D1.
Study: NCT05068193
Drug: BR2008-1 (R)
Normalized name: (R)-LACOSAMIDE 1
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After fasting at least 10 hours, two tablets of BR2008-1 will be administered orally with 150mL of water around 8 a.m.
Study: NCT05068193
Drug: BR2008 (T)
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After fasting at least 10 hours, one tablet of BR2008 will be administered orally with 150mL of water around 8 a.m.
Study: NCT00398957
Drug: OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05682586
Drug: paxlovid
Normalized name: Paxlovid
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive standard dose of paxlovid therapy, which contains 300mg namatevir and 100mg litonavir twice a day for a total course of 5 days.
Study: NCT06668896
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each arm will administer different amounts of progesterone vaginally (8mg to 100mg) over a 14-15 day time period.
Study: NCT06522581
Drug: Citicoline Sodium
Normalized name: Citicoline Sodium
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth
Study: NCT04699071
Drug: pembrolizumab and lenvatinib
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive oral lenvatinib daily plus intravenous pembrolizumab 3-weekly.~A cycle is 21 days. Allowances will be made for stepwise dose reductions of lenvatinib due to treatment-related toxicities.~Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, (CTCAE) Version 5.0.~Patients are planned to continue therapy until disease progression, intolerable toxicity, or withdrawal of patient consent.
Study: NCT04914078
Drug: Mepolizumab 100 MG
Normalized name: mepolizumab 100 MG
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients will treated with subcutaneous Mepolizumab at 100 mg every 30 days. Patients will be recruited among those eligible to Mepolizumab treatment according to the Italian Medicine Agency (AIFA; Agenzia Italiana del Farmaco) guidelines who will accept to participate to the study. In particular inclusion criteria will be: severe (Step 4 and 5 GINA) asthma with at least blood eosinophilic count above 300 cells/mcl at least once in the previous year and ≥150 cells/mcl in the absence of systemic corticosteroid treatment before biological treatment initiation. In addition, one of the following conditions will be required: 1) ≥2 exacerbations in the previous year despite appropriate inhaled treatments or 2) the need for systemic corticosteroids on top of inhaled treatment for at least 6 months in the previous year.
Study: NCT05924152
Drug: Adagrasib
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adagrasib
Study: NCT05924152
Drug: Eltrombopag + adagrasib
Normalized name: Adagrasib
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag + adagrasib
Study: NCT06734702
Drug: Consolidative immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the completion of chemoradiotherapy, Tislelizumab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total duration of 1 year, starting 1-2 months after chemoradiotherapy.
Study: NCT00987233
Drug: triamcinolone acetonide aqueous nasal spray (Apotex Inc.)
Normalized name: triamcinolone acetonide Metered Dose Nasal Spray
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
Study: NCT00987233
Drug: triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)
Normalized name: triamcinolone acetonide Metered Dose Nasal Spray
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
Study: NCT06365671
Drug: Relmacabtagene autoleucel (relma-cel)
Normalized name: ciltacabtagene autoleucel
DrugBank: Relmacabtagene autoleucel (DB18979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: relma-cel (CD19 CAR-T cell)infusion on day 3(±1d) after ASCT with a fixed dose of 100X10\^6.
Study: NCT04729062
Drug: Pegcetacoplan
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Complement (C3) Inhibitor
Study: NCT05246007
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine will be infused at a rate of 0.02 ml/kg/h (0.025 μg/kg/h) during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
Study: NCT06034860
Drug: MT-8421
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment with MT-8421
Study: NCT06034860
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts
Study: NCT01798940
Drug: Torrent's Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05235217
Drug: Test product (T) 40 mg Hard Gelatin Capsules
Normalized name: Hard Gelatin Capsule Shell
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard Gelatin Capsules products containing 40 mg Esomeprazole
Study: NCT05235217
Drug: Reference product (R) 40 mg Hard Gelatin Capsules
Normalized name: Hard Gelatin Capsule Shell
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (R) 40 mg Hard Gelatin Capsules
Study: NCT05018117
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The effects of over-the-counter nicotine gum will be compared to a placebo gum
Study: NCT00002386
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002386
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002386
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002386
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002386
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002386
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05921968
Drug: Lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg twice daily orally before breakfast and dinner
Study: NCT05759845
Drug: Topiramate 25Mg Tab
Normalized name: TOPIRAMATE 25MG TAB
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks
Study: NCT05759845
Drug: Amitriptyline 25 Mg Oral Tablet
Normalized name: amitriptyline 25 mg oral tablet
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
Study: NCT05759845
Drug: topiramate 25mg plus amitriptyline 25mg
Normalized name: topiramate 25 MG
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks with Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
Study: NCT05470868
Drug: Naphazoline / Hypromellose Ophthalmic
DrugBank: Naphazoline (DB06711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naphazoline 0.03% / Hypromellose 0.2%
Study: NCT05138549
Drug: Astaxanthin
Normalized name: Astaxanthin
DrugBank: Astaxanthin (DB06543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg oral astaxanthin supplement
Study: NCT05119920
Drug: Pilocarpine Ophthalmic Topical Cream, Dose 1
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine Ophthalmic Topical Cream, Dose 1
Study: NCT05119920
Drug: Pilocarpine Ophthalmic Topical Cream, Dose 2
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine Ophthalmic Topical Cream, Dose 2
Study: NCT05119920
Drug: Pilocarpine Ophthalmic Topical Cream, Dose 3
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine Ophthalmic Topical Cream, Dose 3
Study: NCT06735664
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT06735820
Drug: APG-115
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of APG-115 and Selumetinib
Study: NCT06735820
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination therapy of APG-115 and Selumetinib
Study: NCT06736184
Drug: Sodium Zirconium Cyclosilicate (SZC)
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5g/meal\*3meals/day
Study: NCT06736418
Drug: 225Ac-ABD147
Normalized name: 225Ac-HuM195
DrugBank: Lintuzumab satetraxetan AC-225 (DB15053)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A delta-like ligand 3 (DLL3)-targeting antibody fragment conjugated with a linker-chelator that effectively coordinates Ac-225
Study: NCT06734260
Drug: Keverprazan Hydrochloride tablets + high dose amoxicillin
Normalized name: amoxicillin Chewable Tablet
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 3 times/day, oral, for 14 day
Study: NCT00000639
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000639
Drug: Flucytosine
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000639
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000639
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04914741
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
Study: NCT04914741
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine 1.4mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
Study: NCT04914741
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glofitamab will be administered by IV infusion as per the schedule specified in the respective arm
Study: NCT04914741
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab 1.8mg/kg administered by IV infusion on Day 1 of every 21-day cycle
Study: NCT05580861
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfazalazine 500mg-tablets ; 7 dose levels explored in the phase I part of the trial.
Study: NCT05164159
Drug: propofol group
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 \~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.
Study: NCT05164159
Drug: remimazolam group
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
Study: NCT05156658
Drug: Etonogestrel (ENG) Subdermal Implants
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etonogestrel is available as a single, white/off-white, soft, radiopaque, flexible, ethylene vinyl acetate copolymer implant, 4 cm in length and 2 mm in diameter containing 68 mg of etonogestrel. Store at 25°C (77°F); excursions permitted between 15 and 30°C (59-86°F) \[see USP Controlled Room Temperature\]. Avoid storing ENG at temperatures above 30°C (86°F).
Study: NCT05917405
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)
Study: NCT05917405
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
Study: NCT05917405
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)
Study: NCT05917405
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)
Study: NCT06734260
Drug: Keverprazan Hydrochloride tablets + low dose amoxicillin
Normalized name: amoxicillin Chewable Tablet
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 2 times/day, oral, for 14 day
Study: NCT06734260
Drug: Keverprazan Hydrochloride tablets + high dose amoxicillin（H-KA-10d）
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 3 times/day, oral, for 10 day
Study: NCT06041646
Drug: Sublingual film containing Igalmi
Normalized name: dexmedetomidine Sublingual Film [Igalmi]
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual film containing 180 µg of Igalmi (dexmedetomidine)
Study: NCT06734182
Drug: Envafolimab injections+intravenous Disitamab Vedotin+carboplatin
Normalized name: carboplatin Injectable Solution
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Biological: Envafolimab 300 mg by subcutaneous injections every 3 weeks (Q3W), given on cycle day 1; Biological: Disitamab Vedotin 2.5mg/kg by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;
Study: NCT06735430
Drug: Ciprofol
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofol for anesthesia induction (0.5mg / kg) and anesthesia maintenance (1-2.5mg/ (kg·h))
Study: NCT06735430
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol for anesthesia induction (2mg / kg) and maintenance of anesthesia (4-10 mg / (kg·h))
Study: NCT06071481
Drug: Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol 4,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol
Study: NCT04787991
Drug: Nivolumab (Cohort A)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered intravenously at 360 mg every 3 weeks for up to 2 years.